homepage-top-section

This applies to patients previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. The approval broadens Jaypirca’s label to cover patients at an earlier stage of treatment

The therapy is intended for patients who have undergone at least three previous therapies, including an immunomodulatory agent and a proteasome inhibitor. The approval is the first authorisation

The decision is intended for those who have previously been treated with a Bruton’s tyrosine kinase (BTK) inhibitor. This application is based on data from a global, open-label,

The deal sets the vaccine price at $2.99 per dose and is expected to take effect within a year, supporting Gavi’s goal to fully vaccinate 50 million more

The agreement includes an exclusivity period of six months for negotiating and finalising a definitive agreement, pending due diligence and board approvals. Vaximm is eligible for an upfront

The authorisations cover Gobivaz in both 100mg/ml and 50mg/0.5ml formulations, provided in pre-filled syringes with autoinjector formats and passive needle safety guards, to treat adults with axial spondyloarthritis,

This is in breach of the Texas Health Care Program Fraud Prevention Act. The ADHD drugs case centred on the medication Quillivant XR, provided to children on Medicaid.

The approval follows positive results from the Phase I/II GO29781 study, which demonstrated that Lunsumio SC has pharmacokinetic non-inferiority to intravenous (IV) administration. No unexpected safety issues were

The acquisition brings Halda’s lead candidate, HLD-0915, a clinical-stage treatment for prostate cancer, into Johnson & Johnson’s oncology portfolio. This once-daily therapy presents an opportunity to enhance patient